Legacy of Alembic Pharmaceuticals Limited (APL) dates back to over 100 years. Established in 1907 with an objective to develop and revolutionize the Pharmaceutical and Drug industry in the Indian subcontinent, Alembic Pharmaceuticals Limited today is one of the leading pharmaceutical companies in India.

Zydus, a leading discovery-based, global pharmaceutical company announced today that it has received permission to initiate the Phase II (a) clinical study of its NLRP3 inhibitor ZYIL1 in patients with Cryopyrin-Associated Periodic Syndrome (CAPS) in Australia. Phase II (a) clinical trial in Australia will study the safety, tolerability, pharmacokinetics and pharmacodynamics in patients with Cryopyrin- Associated Periodic Syndrome (CAPS).

PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), today announced the closing of the previously announced acquisition of Lyophilization Services of New England, Inc. (LSNE), a premier contract development and manufacturing organization headquartered in Bedford, New Hampshire.

The newly relaunched device is a handheld, lightweight solution that improves breathing and strengthens the lungs. With AirPhysio, chronic bronchitis sufferers can reduce mucus buildup in five minutes or less per day.

Applications are invited from eligible candidates for filling up the following posts under National Health Mission, ZSS, Cuttack on contractual basis for a period of 11 months with monthly remuneration as noted against each and subject to renewal as per Society norms basing on the performance and subject to continuance of the programme. Performance Incentives & other benefits are also admissible for all posts as per norms applicable and orders issued there-under from time to time.

The National Innovation Foundation – India, is India's national initiative to strengthen the grassroots technological innovations and outstanding traditional knowledge. Its mission is to help India become a creative and knowledge-based society by expanding policy and institutional space for grassroots technological innovators. NIF scouts, supports and spawns' grassroots innovations developed by individuals and local communities in any technological field, helping in human survival without any help from formal sector.

The CSIR-National Botanical Research Institute is amongst one of the constituent research institutes of the Council of Scientific and Industrial Research (CSIR), New Delhi. Originally set up as the National Botanic Gardens (NBG) by the State Government of Uttar Pradesh  it was taken over by the CSIR in 1953.

Applications are invited through offline mode (Physical applications) from the eligible candidates for recruitment to the below mentioned posts on Contract / Outsourcing basis under the control of Director of Medical Education to work in SVRR Government General Hospital, Tirupati, Chittoor district.

Post : Pharmacist Gr-II

Notification for the recruitment drive for the post of Pharmacists Grade- II in Urban Primary Health Centre’s on Contract Basis Under the Administrative Control of District Medical &Health Officer, Vizianagaram.

The Indian Council of Medical Research (ICMR), New Delhi, the apex body in India for the formulation, coordination and promotion of biomedical research, is one of the oldest medical research bodies in the world. The ICMR has always attempted to address itself to the growing demands of scientific advances in biomedical.

The National Institute of Mental Health and Neuro Sciences (NIMHANS) is a multidisciplinary institute for patient care and academic pursuit in the field of mental health and neurosciences. NIMHANS is synonymous with providing high standards of clinical care, quality training and cutting-edge research in the frontier areas. Combined priorities for comprehensive patient care, manpower development and research, stem from the commitment to an integrated and multidisciplinary approach which addresses societal needs.

CSIR-CCMB is a premier constituent research Institute of the Council of Scientific and Industrial Research (CSIR), conducting research in frontier areas of modern biology. The objectives of the Centre are to conduct high-quality basic research and training in the areas of modern biology and promote centralized national facilities for new and modern techniques in the inter-disciplinary areas of biology.

Bengal College of Pharmaceutical Science & Research was established in the year 2008 by SKS Educational and Social Trust, having an impressive campus and is dedicated to develop and nurture pharmaceutical education and research. The campus gives an aesthetic and pleasant look where it will be our endeavor to produce the best graduates in a learner-focused environment.

Torrent Pharma, the flagship company of Torrent Group, is ranked amongst the top pharma companies of India. It is a dominant player in the therapeutic areas of cardiovascular (CV) and central nervous system (CNS) and has achieved significant presence in gastro-intestina, diabetology, anti-infective and pain management segments. Torrent Pharma has a strong international presence spanning over 70 countries with over 1200 product registrations.

Teva is a global pharmaceutical leader and the world’s largest generic medicines producer, committed to improving health and increasing access to quality health solutions worldwide.  Our employees are at the core of our success, with colleagues in over 80 countries delivering the world’s largest medicine cabinet to 200 million people every day. We offer a uniquely diverse portfolio of products and solutions for patients and we’ve built a promising pipeline centered around our core therapeutic areas.

Lupin Limited (Lupin) has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (US FDA) for its Goa manufacturing facility, after the inspection of the facility in September 2021. The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI).

OKYO Pharma Limited a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases (DED) and ocular pain, is pleased to announce that its drug candidate OK-101 which was developed to treat DED through its anti-inflammatory mode of action also shows potent ocular pain reducing property determined using a mouse model of corneal neuropathic pain, establishing the potential to treat both pain and inflammation, the most common symptoms of dry eye, with a single drug.

Acacia Pharma Group plc a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or cancer chemotherapy, announces the successful completion of its post-approval requirement clinical trial investigating the effects of BARHEMSYS® (amisulpride injection) in individuals with severe renal impairment.

A study of an investigational gene therapy for sickle cell disease has found that a single dose restored blood cells to their normal shape and eliminated the most serious complication of the disease for at least three years in some patients.